Search in PubMed with “drug-induced cholestasis” and “bile canaliculi” retrieved the following publications:

  • Drug Metab Dispos. 2016;44:1780-1793. Early alterations of bile canaliculi dynamics and the Rho Kinase/Myosin Light Chain Kinase pathway are characteristics of drug-induced intrahepatic cholestasis. Burbank MG, Burban A, Sharanek A, Weaver RJ, Guguen-Guillouzo C, Guillouzo A. PubMed
  • Nucl Med Biol. 2016;43:642-9. IMAGING Synthesis, in vitro and in vivo small-animal SPECT evaluation of novel technetium labeled bile acid analogues to study (altered) hepatic transporter function. Neyt S, Vliegen M, Verreet B, De Lombaerde S, Braeckman K, Vanhove C4, Huisman MT, Dumolyn C, Kersemans K, Hulpia F, Van Calenbergh S, Mannens G, De Vos F. PubMed
  • Sci Rep. 2016;6:24709. Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs. Sharanek A, Burban A, Burbank M, Le Guevel R, Li R, Guillouzo A, Guguen-Guillouzo C. PubMed
  • Mol Pharm. 2016;13:163-71. Flagging drugs that inhibit the bile salt export pump. Montanari F, Pinto M, Khunweeraphong N, Wlcek K, Sohail MI, Noeske T, Boyer S, Chiba P, Stieger B, Kuchler K, Ecker GF. PubMed
  • Intensive Care Med. 2016;42:16-27. Cholestatic liver (dys)function during sepsis and other critical illnesses. Jenniskens M, Langouche L, Vanwijngaerden YM, Mesotten D, Van den Berghe G. PubMed
  • Arch Toxicol. 2015;89:1861-70.  Bile canalicular dynamics in hepatocyte sandwich cultures. Reif R, Karlsson J, Günther G, Beattie L, Wrangborg D, Hammad S, Begher-Tibbe B, Vartak A, Melega S, Kaye PM, Hengstler JG, Jirstrand M. PubMed
  • Arch Pathol Lab Med. 2015;139:858-66. Pathophysiology and diseases of the proximal pathways of the biliary system. Nakanishi Y, Saxena R. PubMed
  • Toxicol Sci. 2015;145:157-68. Comparative localization and functional activity of the main hepatobiliary transporters in HepaRG cells and primary human Hepatocytes. Bachour-El Azzi P, Sharanek A, Burban A, Li R, Guével RL, Abdel-Razzak Z, Stieger B, Guguen-Guillouzo C, Guillouzo A. PubMed
  • Arch Toxicol. 2015;89:979-90. Sandwich-cultured rat hepatocytes as an in vitro model to study canalicular transport alterations in cholestasis. Miszczuk GS, Barosso IR, Zucchetti AE, Boaglio AC, Pellegrino JM, Sánchez Pozzi EJ, Roma MG, Crocenzi FA. PubMed
  • Toxicol Sci. 2014;141:244-53.  Different dose-dependent mechanisms are involved in early cyclosporine a-induced cholestatic effects in hepaRG cells. Sharanek A, Azzi PB, Al-Attrache H, Savary CC, Humbert L, Rainteau D, Guguen-Guillouzo C, Guillouzo A. PubMed
  • Drug Metab Dispos. 2014;42:566-74. Drug-induced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: mechanistic considerations beyond the direct inhibition of the bile salt export pump. Rodrigues AD, Lai Y, Cvijic ME, Elkin LL, Zvyaga T, Soars MG. PubMed  Erratum in Drug Metab Dispos. 2014;42:1978.
  • Hepatology. 2014;59:1016-29. G-protein-coupled receptor 30/adenylyl cyclase/protein kinase A pathway is involved in estradiol 17ß-D-glucuronide-induced cholestasis. Zucchetti AE, Barosso IR, Boaglio AC, Basiglio CL, Miszczuk G, Larocca MC, Ruiz ML, Davio CA, Roma MG, Crocenzi FA, Pozzi EJ. PubMed
  • J Biol Chem. 2011;286:45014-29. The Src family kinase Fyn mediates hyperosmolarity-induced Mrp2 and Bsep retrieval from canalicular membrane. Cantore M, Reinehr R, Sommerfeld A, Becker M, Häussinger D. PubMed
  • Mol Pharmacol. 2011;79:241-50. Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4. Yoshikado T, Takada T, Yamamoto T, Yamaji H, Ito K, Santa T, Yokota H, Yatomi Y, Yoshida H, Goto J, Tsuji S, Suzuki H. PubMed
  • Hepatology. 2010;52:1465-76. Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17β-D-glucuronide-induced cholestasis: complementarity with classical protein kinase C. Boaglio AC, Zucchetti AE, Sánchez Pozzi EJ, Pellegrino JM, Ochoa JE, Mottino AD, Vore M, Crocenzi FA, Roma MG. PubMed